A Phase 1b trial of ficlatuzumab plus the EGFR TKI gefitinib in Asian patients with advanced NSCLC demonstrated acceptable tolerability with an objective response rate of 33% [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.